Australia's most trusted
source of pharma news
Posted 6 June 2025 PM
The TGA has added a class-wide warning for GLP-1 and dual GIP/GLP-1 receptor agonists about the risk of aspiration during general anaesthesia and deep sedation after conducting an independent assessment.
GLP-1 medicines currently marketed in Australia include three diabetes treatments – Novo Nordisk’s Ozempic and Victoza, plus Eli Lilly’s Trulicity – along with Novo Nordisk’s Saxenda and Wegovy, which are approved for chronic weight management in patients who are obese or overweight.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.